Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma

This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single i...

Descripción completa

Detalles Bibliográficos
Autores principales: Suekane, Shigetaka, Ueda, Kousuke, Nishihara, Kiyoaki, Sasada, Tetsuro, Yamashita, Takuto, Koga, Noriko, Yutani, Shigeru, Shichijo, Shigeki, Itoh, Kyogo, Igawa, Tsukasa, Noguchi, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715265/
https://www.ncbi.nlm.nih.gov/pubmed/28940789
http://dx.doi.org/10.1111/cas.13404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715265/
https://www.ncbi.nlm.nih.gov/pubmed/28940789
http://dx.doi.org/10.1111/cas.13404

Ejemplares similares